In this episode of Biotech Bulls & Breakthroughs, John sits down with Michael Heltzen, CEO of exoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how exoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market.

eXoZymes Inc.
https://www.biopharmcatalyst.com/company/EXOZ#/

📲 Follow Michael Heltzen and eXoZymes: https://www.linkedin.com/in/michaelheltzen
https://www.linkedin.com/company/exozymes
https://exozymes.com/

In this episode:

🔹 Why "cell-free" systems outperform traditional cell fermentation.
🔹 How AI is used to "speed run" evolution for enzyme development
🔹 Insights into the 2024 exoZymes IPO and their commercial roadmap.

🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
📲 Follow Sheff: https://x.com/SheffStation

Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.